Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?

Hung AY, Schwarzschild MA.

Curr Opin Neurol. 2007 Aug;20(4):477-83. Review.

PMID:
17620885
2.

Designing neuroprotection trials in Parkinson's disease.

Kieburtz K.

Ann Neurol. 2003;53 Suppl 3:S100-7; discussion S107-9. Review.

PMID:
12666102
3.

Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.

Löhle M, Reichmann H.

J Neurol Sci. 2010 Feb 15;289(1-2):104-14. doi: 10.1016/j.jns.2009.08.025. Epub 2009 Sep 20. Review.

PMID:
19772974
4.

Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?

Clarke CE.

Mov Disord. 2008 Apr 30;23(6):784-9. doi: 10.1002/mds.21918.

PMID:
18175348
5.

Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.

Naoi M, Maruyama W.

Expert Rev Neurother. 2009 Aug;9(8):1233-50. doi: 10.1586/ern.09.68.

PMID:
19673610
6.

Why have we failed to achieve neuroprotection in Parkinson's disease?

Olanow CW, Kieburtz K, Schapira AH.

Ann Neurol. 2008 Dec;64 Suppl 2:S101-10. doi: 10.1002/ana.21461. Review.

PMID:
19127580
7.

The use of rasagiline in Parkinson's disease.

Schapira AH.

J Neural Transm Suppl. 2006;(71):157-61. Review.

PMID:
17447426
8.

Issues in neuroprotection clinical trials in Parkinson's disease.

Kieburtz K.

Neurology. 2006 May 23;66(10 Suppl 4):S50-7.

PMID:
16717252
9.

Trial designs used to study neuroprotective therapy in Parkinson's disease.

Lang AE, Melamed E, Poewe W, Rascol O.

Mov Disord. 2013 Jan;28(1):86-95. doi: 10.1002/mds.24997. Epub 2012 Aug 23. Review.

PMID:
22927060
10.
11.

Disease modification in Parkinson's disease.

Henchcliffe C, Severt WL.

Drugs Aging. 2011 Aug 1;28(8):605-15. doi: 10.2165/11591320-000000000-00000. Review.

PMID:
21812497
12.

Neuroprotection in Parkinson's disease: an elusive goal.

Biglan KM, Ravina B.

Semin Neurol. 2007 Apr;27(2):106-12. Review.

PMID:
17390255
13.

Trials of neuroprotective therapies for Parkinson's disease: problems and limitations.

de la Fuente-Fernández R, Schulzer M, Mak E, Sossi V.

Parkinsonism Relat Disord. 2010 Jul;16(6):365-9. doi: 10.1016/j.parkreldis.2010.04.008. Epub 2010 May 14. Review.

PMID:
20471298
14.

Neuroprotection in Parkinson's disease: clinical trials.

Stocchi F, Olanow CW.

Ann Neurol. 2003;53 Suppl 3:S87-97; discussion S97-9. Review.

PMID:
12666101
15.

A responsive outcome for Parkinson's disease neuroprotection futility studies.

Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, Palesch YY, Huang P, Guimaraes P, Kamp C, Tilley BC, Kieburtz K; NET-PD Investigators.

Ann Neurol. 2005 Feb;57(2):197-203.

PMID:
15668964
16.

Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.

Meissner W, Hill MP, Tison F, Gross CE, Bezard E.

Trends Pharmacol Sci. 2004 May;25(5):249-53. Review.

PMID:
15120490
17.

Progress in neuroprotection in Parkinson's disease.

Schapira AH.

Eur J Neurol. 2008 Apr;15 Suppl 1:5-13. doi: 10.1111/j.1468-1331.2008.02055.x. Review.

PMID:
18353131
18.

Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.

Chen JJ, Ly AV.

Am J Health Syst Pharm. 2006 May 15;63(10):915-28. Review.

PMID:
16675649
19.

Concerning neuroprotective therapy for Parkinson's disease.

Uitti RJ, Wszolek ZK.

J Neural Transm Suppl. 2006;(70):433-7. Review.

PMID:
17017564
20.

Supplemental Content

Support Center